This micro-blog is specifically for a discussion of equities trading in Pre-Market or After-Market, Or Extremely URGENT, verifiable News relating to Global Markets.
It may also include certain nuances in specific markets and sharing of information with others on their Standard Operating Procedures, as well as access to those markets.
Have FUN, keep it real and enjoy each others company, tidbits of advice, humor, expertise or lack thereof. The Gummunity is a Sharing and Caring environment; Please Keep It Clean.
Bes2ALL! – >>>–BenJammmin’——->
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
#APTO full poster link at #ASH22
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase
Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Full poster link: https://d1io3yog0oux5.cloudfront.net/_9bafa6459ca6d34eef83d9ee5d4d2573/aptose/db/776/7419/pdf/ASH+2022+Poster+-+Tuspetinib+Phase+1.2+Trial.pdf
#ThankYOU
@GantosJ
$APTO #AML #patients LOVE!
$ONCT Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
https://www.1stoncology.com/blog/oncternal-therapeutics-presents-updated-interim-data-for-zilovertamab-in-combination-with-ibrutinib-at-ash-20221234625027/
$APTO Form 424b5 http://archive.fast-edgar.com/20221212/AA23MQ2CZ22ENZZZ272B2ZE5HGDRZZ22Z242/
Best Alwwayz